EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia

Andrew Wu, Min Chen, Athena Phoa, Zesong Yang, Donna L Forrest, Xiaoyan Jiang iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26136533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Andrew Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canad…. Hauptthemen laut MEDLINE: p21-Activated Kinases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-mdm2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Cancer Society, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a leading example of a malignancy where a molecular targeted therapy revolutionized treatment but has rarely led to cures. Overcoming tyrosine kinase inhibitor (TKI) drug resistance remains a challenge in the treatment of CML. We have recently identified miR-185 as a predictive biomarker where reduced expression in CD34+ treatment-naïve CML cells was associated with TKI resistance. We have also identified PAK6 as a target gene of miR-185 that was upregulated in CD34+ TKI-nonresponder cells. However, its role in regulating TKI resistance remains largely unknown. In this study, we specifically targeted PAK6 in imatinib (IM)-resistant cells and CD34+ stem/progenitor cells from IM-nonresponders using a lentiviral-mediated PAK6 knockdown strategy. Interestingly, the genetic and pharmacological suppression of PAK6 significantly reduced proliferation and increased apoptosis in TKI-resistant cells. Cell survivability was further diminished when IM was combined with PAK6 knockdown. Importantly, PAK6 inhibition in TKI-resistant cells induced cell cycle arrest in the G2-M phase and cellular senescence, accompanied by increased levels of DNA damage-associated senescence markers. Mechanically, we identified a PAK6-mediated MDM2-p21 axis that regulates cell cycle arrest and senescence. Thus, PAK6 plays a critical role in determining alternative cell fates in leukemic cells, and targeting PAK6 may offer a therapeutic strategy to selectively eradicate TKI-resistant cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

p21-Activated KinasesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmProto-Oncogene Proteins c-mdm2Neoplastic Stem CellsCyclin-Dependent Kinase Inhibitor p21HumansCell SurvivalCell Line, TumorApoptosisCell ProliferationImatinib MesylateCell Cycle CheckpointsProtein Kinase InhibitorsMicroRNAsSignal Transduction

Stichwörter der Autor:innen

CMLDNA damageImatinibPAK6TKI resistanceTKI therapycell cycleleukemic stem cellssenescencesmall molecule inhibitors

Substanzen

p21-Activated KinasesProto-Oncogene Proteins c-mdm2MDM2 protein, humanPAK6 protein, humanCyclin-Dependent Kinase Inhibitor p21Imatinib MesylateProtein Kinase InhibitorsMicroRNAsCDKN1A protein, human

Autor:innen und Institutionen

  • Collings Stevens Chronic Leukemia Research Laboratory, Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
  • Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
  • Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China.
  • Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, BC V5Z 1M9, Canada.
  • Department of Medical Genetics, University of British Columbia; Vancouver, BC V6T 1Z4, Canada.

ORCID-Profile: Xiaoyan Jiang

Förderung

  • CIHR
  • Canadian Cancer Society
  • Canadian Institutes of Health Research
  • Collings Stevens Chronic Leukemia Research Fund
  • MITACS Accelerate Fellowship
  • Michael Smith Health Research BC Postdoctoral Trainee Award

Zitieren

APA

Wu, A., Chen, M., Phoa, A., Yang, Z., Forrest, D. L., & Jiang, X. (2025). Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136533

Vancouver

Wu A, Chen M, Phoa A, Yang Z, Forrest DL, Jiang X. Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136533

BibTeX
@article{Wu2025,
  author = {Wu, Andrew and Chen, Min and Phoa, Athena and Yang, Zesong and Forrest, Donna L and Jiang, Xiaoyan},
  title = {Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26136533}
}
Kostenlos starten →